Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0204)
Name
Oxaliplatin
Synonyms
oxaliplatin; DTXSID0036760; Oxalato(trans-l-1,2-cyclohexanediamine)platinum(II); cis-oxalato-trans-l-1,2-diaminocyclohexaneplatinum(II); DTXCID8016760; CAS-61825-94-3; NCGC00167798-01; SCHEMBL19511; HMS3269F19; Tox21_112585; Tox21_112629; AKOS005766023; AKOS015855804; CS-0992; BP-25383; HY-17371; [(1S,2S)-2-azanidylcyclohexyl]azanide; oxalate; platinum(4+)

    Click to Show/Hide
Structure
3D MOL
2D MOL
Formula
C8H14N2O4Pt
IUPAC Name
[(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+)
Canonical SMILES
C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
InChI
InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1
InChIKey
DRMCATBEKSVAPL-BNTLRKBRSA-N
PubChem CID
9887053
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Hepatocellular carcinoma ICD-11: 2C12
 Disease Info 
Responsed Regulator LINC01134 (IncRNA) Suppressor
 Regulator Info 
Pathway Response Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
Huh-7 cells Hepatocellular carcinoma Homo sapiens CVCL_0336
Response regulation LINC01134 was positively correlated with GPX4 or Nrf2, demonstrating the clinical significance of LINC01134, Nrf2 and GPX4 in OXA resistance of hepatocellular carcinoma (HCC). Silenced LINC01134 enhances Oxaliplatin sensitivity by facilitating ferroptosis through GPX4 in hepatocarcinoma.
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
 Target Info 
In total 2 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Hepatocellular carcinoma ICD-11: 2C12
 Disease Info 
Responsed Regulator LINC01134 (IncRNA) Suppressor
 Regulator Info 
Pathway Response Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
Huh-7 cells Hepatocellular carcinoma Homo sapiens CVCL_0336
Response regulation LINC01134 was positively correlated with GPX4 or Nrf2, demonstrating the clinical significance of LINC01134, Nrf2 and GPX4 in OXA resistance of hepatocellular carcinoma. Silenced LINC01134 enhances Oxaliplatin sensitivity by facilitating ferroptosis through GPX4 in hepatocarcinoma.
Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target [2]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model HT29 cells Colon cancer Mus musculus CVCL_A8EZ
Response regulation Oxaliplatin promoted ferroptosis and oxidative stress in colorectal cancer cells by inhibiting the Nrf2 signaling pathway. Treatment with oxaliplatin enhanced the effects of erastin on CRC cells by promoting ferroptosis and oxidative stress and inhibiting cell viability.
References
Ref 1 Silenced LINC01134 Enhances Oxaliplatin Sensitivity by Facilitating Ferroptosis Through GPX4 in Hepatocarcinoma. Front Oncol. 2022 Jul 8;12:939605. doi: 10.3389/fonc.2022.939605. eCollection 2022.
Ref 2 Oxaliplatin induces ferroptosis and oxidative stress in HT29 colorectal cancer cells by inhibiting the Nrf2 signaling pathway. Exp Ther Med. 2022 Jun;23(6):394. doi: 10.3892/etm.2022.11321. Epub 2022 Apr 13.